Effect of Cilostazol as an add-on Treatment to a Single Antiplatelet Agent (Acetylsalicylic Acid or Clopidogrel) on Platelet Function Testing and Bleeding Time in Healthy Volunteers

Trial Profile

Effect of Cilostazol as an add-on Treatment to a Single Antiplatelet Agent (Acetylsalicylic Acid or Clopidogrel) on Platelet Function Testing and Bleeding Time in Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Cilostazol (Primary) ; Aspirin; Clopidogrel
  • Indications Angina pectoris; Arterial occlusive disorders; Coronary artery restenosis; Intermittent claudication; Stroke
  • Focus Therapeutic Use
  • Acronyms CiloMecT
  • Sponsors Otsuka Pharmaceutical
  • Most Recent Events

    • 24 Jul 2017 Planned End Date changed from 1 Apr 2017 to 1 Dec 2017.
    • 24 Jul 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.
    • 23 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top